CUSIP: 62957M104
Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / SPONSORED ADR
-
Total 13F shares
-
15,205,809
-
Share change
-
+329,383
-
Total reported value
-
$182,434,000
-
Price per share
-
$11.99
-
Number of holders
-
25
-
Value change
-
+$4,300,138
-
Number of buys
-
8
-
Number of sells
-
9
Quarterly Holders Quick Answers
What is CUSIP 62957M104?
CUSIP 62957M104 identifies NBRV - NABRIVA THERAPEUTICS AG - SPONSORED ADR in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2017
-
Previous quarter:
Q4 2016
Recent filing periods for CUSIP 62957M104:
Institutional Holders of NABRIVA THERAPEUTICS AG - SPONSORED ADR (NBRV) as of Q1 2017
As of 31 Mar 2017,
NABRIVA THERAPEUTICS AG - SPONSORED ADR (NBRV) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,205,809 shares.
The largest 10 holders included
Vivo Capital, LLC, Novo A/S, WELLINGTON MANAGEMENT GROUP LLP, ORBIMED ADVISORS LLC, Omega Fund Management, LLC, Hillhouse Capital Management, Ltd., ACUTA CAPITAL PARTNERS, LLC, Rock Springs Capital Management LP, FRANKLIN RESOURCES INC, and BAKER BROS. ADVISORS LP.
This page lists
25
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.